ClinicalTrials.gg
Status unknownNCT05275504Updated Jun 9, 2022

Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies

A Phase 1 interventional study of TT-01488 in B-Cell Malignancies, sponsored by TransThera Sciences (Nanjing), Inc.. Status unknown at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-09.

Sponsored by TransThera Sciences (Nanjing), Inc. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
37
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a first-in-human (FIH), multicenter, open-label Phase I dose escalation study to evaluate the safety and preliminary efficacy of the TT-01488 tablet, a non-covalent reversible BTK inhibitor, for the treatment of adult patients with B-cell malignancies.

Read the detailed description

The study will consist of two parts, dose escalation and dose expansion. A modified 3+3 design will be used to guide the dose escalation and the determination of the dose recommended for dose expansion (DRDE). A sentinel cohort comprising of one subject will be enrolled at a starting dose of 50 mg q.d. Subsequently, patients will be enrolled according to the standard 3+3 dose escalation design to determine the DRDE. Once the DRDE has been selected, TT-01488 of DRDE will be further tested in the dose expansion cohort to verify the safety and preliminary efficacy as observed in the dose escalation cohorts. A recommended Phase II dose (RP2D) may be determined based on the totality of safety, pharmacokinetics, and efficacy data from the dose escalation cohorts and dose expansion cohort.

02

Conditions studied

  • B-Cell Malignancies

Keywords

  • B-Cell Malignancies
  • Non-Hodgkin's Lymphomas (NHL)
  • BTK inhibitor
  • C481S mutation
03

In context

Lead sponsor

TransThera Sciences (Nanjing), Inc. is the lead sponsor of 19 studies on the registry; 7 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women ≥ 18 years of age with or cytologically confirmed R/R B-NHL, including but not limited to chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL), Waldenström macroglobulinemia (WM), follicular lymphoma (FL), marginal zone lymphoma (MZL), diffuse large-b-cell lymphomas (DLBCL), and transformed lymphoma who failed or are intolerant to ≥ 1 prior standard of care regimens.

    Notes:

    • Patients with prior treatment of BTK inhibitors are eligible
    • Patients with low grade lymphoma must be progressing and requiring treatment:
    • Patients with CLL must have disease requiring treatment as specified in 2018 IWCLL Guidelines (Appendix 5)
    • Patients with B-cell NHL must have per 2014 Lugano Classification (Appendix 6)
    • Patients with WM must have minimum serum immunoglobulin M (IgM) level of ≥ 2 times the (ULN)
  2. Body weight ≥ 40 kg
  3. (ECOG) performance status of ≤ 2
  4. Adequate organ function, defined by the following laboratory parameters:

    • Hematologic:

      • (ANC) ≥ 750/ul, unless due to bone marrow involvement due to disease
      • ≥ 50,000/ul without transfusion within 7 days
      • ≥ 80 mg/dl without transfusion within 7 days
    • Coagulation:

      • (PT) ≤ 1.5 × ULN
      • Activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN
    • Renal function:

      o ≥ 60 mL/min estimated based on Cockcroft-Gault formula or 24-hour urine collection

    • Liver function:

      • Total ≤ 1.5 × ULN (unless due to Gilbert's disease)
      • (AST) or alanine aminotransferase (ALT) ≤ 2.5 × ULN unless disease-related
  5. Agreement to use during the study and until at least 6 months after the last dose of study drug if sexually active and able to bear children
  6. Willing and able to participate in all required evaluations and procedures in the study protocol including swallowing tablets without difficulty
  7. Ability to understand the purpose and risks of the study and provide signed and dated and authorization to use protected health information (in accordance with national and local subject privacy regulations)

Exclusion criteria

Exclusion Criteria:

  1. Women who are pregnant or lactating
  2. Prior , except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease-free for at least 2 years or which will not limit survival to \< 2 years (Note: these cases must be discussed with the Medical Monitor and/or Investigator)
  3. A life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of TT-01488, or put the study outcomes at undue risk
  4. Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or significant screening abnormalities including left bundle branch block, 2nd degree AV block type II, 3rd degree block, bradycardia, and interval using Fridericia's Formula (QTcF) > 470 msec, or any Class 3 or 4 cardiac disease as defined by the Functional Classification
  5. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction
  6. Any immunotherapy, , radiotherapy (limited-field radiation for palliation within 7 days), or experimental therapy within 4 weeks, or 5-half lives for chemotherapy and small molecule agents (whichever is shorter), before first dose of study drug ( for disease-related symptoms allowed but require 1-week before study drug administration)
  7. History of or autologous stem cell transplant (SCT) or chimeric antigen receptor-modified T-cell (CAR-T) therapy within the past 60 days or with any of the following:

    • Active (GvHD);
    • Cytopenias from incomplete blood cell count recovery post-transplant;
    • Need for anti-cytokine therapy for toxicity from CAR-T therapy; residual symptoms of neurotoxicity > Grade 1 from CAR-T therapy;
    • Ongoing therapy
  8. Concomitant use of prohibited medications(Section 6.4.2), including:

    • Therapeutic doses of warfarin sodium (Coumadin®) or any other coumarin-derivative anticoagulants
    • Medications with known risk to cause QT prolongation or Torsades de pointes
    • Strong inhibitors and inducers (must be discontinued for at least 14 days or 5 half-lives, whichever is longer, before study treatment)
    • Proton pump inhibitors, histamine-2 blockers (H2 blockers), and locally acting antacids (Note: For patients who are dependent upon this class of medications, patients may be considered after consulting with the study investigator and Sponsor. See Section 6.4.2 for more details).
  9. Central nervous system involvement by lymphoma
  10. Grade ≥ 2 toxicity (other than alopecia) continuing from prior anticancer therapy, including radiation
  11. Known history of (HIV) or active infection with Cytomegalovirus (CMV), Virus (HCV) or Virus (HBV), or any uncontrolled active systemic infection
  12. Major surgery within 4 weeks before first dose of study drug
Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
37 participants (estimated)

Study arms

  • Experimental
    Dose Escalation for TT-01488

    TT-01488 tablets will be administered once daily in a 28-day cycle in increasing strength in order to determine the recommended dose for dose expansion.

    Drug: TT-01488

  • Experimental
    Dose Expansion for TT-01488

    TT-01488 tablets will be administered once daily in 28-day cycles to verify the safety and preliminary efficacy as observed in the dose escalation cohorts.

    Drug: TT-01488

Interventions

  • TT-01488 tablet will be administered orally once daily per protocol defined schedule.

06

What researchers measure

Primary outcomes

  1. Dose-Limiting Toxicity (DLT) of TT-01488

    Safety and tolerability of TT-01488 as a single agent

    Time frame: Up to 28 days after first dose

  2. Dose recommend for dose expansion (DRDE)

    Safety and tolerability of TT-01488 as a single agent

    Time frame: 1 - 1.5 years

  3. Maximum Tolerated Dose (MTD), if reached, of TT-01488

    Safety and tolerability of TT-01488 as a single agent

    Time frame: Up to 28 days after first dose

Secondary outcomes

  1. Number of participants with treatment-related adverse events (AEs)

    Safety and tolerability of TT-01488 as a single agent. AEs will be assessed per CTCAE v5.0 and may include, but is not limited to, clinically abnormal laboratory tests, physical exams, vital signs, electrocardiograms, and ECOG performance status.

    Time frame: 1 - 1.5 years

  2. Objective Response Rate (ORR)

    Preliminary efficacy profile of TT-01488 as a single agent

    Time frame: 1 - 1.5 years

  3. Disease Control Rate (DCR)

    Preliminary efficacy profile of TT-01488 as a single agent

    Time frame: 1 - 1.5 years

  4. Duration of Response (DOR)

    Preliminary efficacy profile of TT-01488 as a single agent

    Time frame: 1 - 1.5 years

  5. Progression free survival (PFS)

    Preliminary efficacy profile of TT-01488 as a single agent

    Time frame: 1 - 1.5 years

  6. Overall survival (OS)

    Preliminary efficacy profile of TT-01488 as a single agent

    Time frame: 1 - 1.5 years

  7. Recommended Phase 2 dose (RP2D)

    Safety and tolerability of TT-01488 as a single agent

    Time frame: 1 - 1.5 years

  8. Area under the concentration time curve (AUC 0-last)

    Pharmacokinetic (PK) profile of TT-01488 as a single agent

    Time frame: 1 - 1.5 years

  9. Maximum plasma concentration (Cmax)

    Pharmacokinetic (PK) profile of TT-01488 as a single agent

    Time frame: 1 - 1.5 years

  10. Time to Maximum Plasma Concentration (Tmax)

    Pharmacokinetic (PK) profile of TT-01488 as a single agent

    Time frame: 1 - 1.5 years

  11. Half-life (T1/2)

    Pharmacokinetic (PK) profile of TT-01488 as a single agent

    Time frame: 1 - 1.5 years

  12. Mean Residence Time (MRT)

    Pharmacokinetic (PK) profile of TT-01488 as a single agent

    Time frame: 1 - 1.5 years

  13. Volume of Distribution (Vd)

    Pharmacokinetic (PK) profile of TT-01488 as a single agent

    Time frame: 1 - 1.5 years

07

Study locations

1 of 2 sites recruiting
  • Gabrail Cancer Center
    Canton, Ohio 44718, United States
    Recruiting
  • The University of Texas MD Anderson Cancer Center (MDACC)
    Houston, Texas 77030, United States
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2022; primary completion for Sep 2022, 3 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2022
First posted
Mar 11, 2022
StartEst.
Jun 2022
Primary completionEst.
Sep 2022
CompletionEst.
Apr 2023
Last update
Jun 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05275504
Lead sponsor
TransThera Sciences (Nanjing), Inc.
Responsible party
Sponsor
First posted
Mar 11, 2022
Start date
Jun 2022 (estimated)
Primary completion
Sep 2022 (estimated)
Completion
Apr 2023 (estimated)
Last update
Jun 9, 2022

Study contacts

Caixia Sun, PhD
Contact
clinicaltrial@transtherabio.com
025-58216298
Nitin Jain, MD
principal investigator · The University of Texas MD Anderson Cancer Center (MDACC)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BTK Inhibitor TT-01488

Start the discussion